184 related articles for article (PubMed ID: 34902266)
1. Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an
Huang J; Guo S; Li X; Yuan F; Li Y; Xu B; Gu J; Qiao Y
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0180021. PubMed ID: 34902266
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
3. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
Li Z; Liu Y; Wang R; Li A
World J Microbiol Biotechnol; 2014 Nov; 30(11):2927-32. PubMed ID: 25129332
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
[TBL] [Abstract][Full Text] [Related]
8. Genetic mutations in the quinolone resistance-determining region are related to changes in the epidemiological profile of methicillin-resistant Staphylococcus aureus isolates.
de Oliveira TLR; Cavalcante FS; Chamon RC; Ferreira RBR; Dos Santos KRN
J Glob Antimicrob Resist; 2019 Dec; 19():236-240. PubMed ID: 31176072
[TBL] [Abstract][Full Text] [Related]
9. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.
Chen YH; Liu CY; Ko WC; Liao CH; Lu PL; Huang CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2014 Feb; 33(2):233-9. PubMed ID: 23955154
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
Rose WE; Fallon M; Moran JJ; Vanderloo JP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
[TBL] [Abstract][Full Text] [Related]
17. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.
Remy JM; Tow-Keogh CA; McConnell TS; Dalton JM; Devito JA
J Antimicrob Chemother; 2012 Dec; 67(12):2814-20. PubMed ID: 22875850
[TBL] [Abstract][Full Text] [Related]
18. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
[TBL] [Abstract][Full Text] [Related]
20. Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.
Zelenitsky S; Alkurdi N; Weber Z; Ariano R; Zhanel G
Antimicrob Agents Chemother; 2011 Jul; 55(7):3627-30. PubMed ID: 21502616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
